HUMA
Humacyte, Inc.
$0.9690
+5.67%
$203.6M
No data for this timeframe.
Vol
Market Cap$203.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders7 funds
Inst. Value$13.7M
Inst. Activity1 buys / 0 sells
Insider Activity2B / 2S
Insider Net $-$22.5K
Reddit Sentiment50° Neutral
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001818382·Prev Close $0.9170
Recent Activity
May 20, 2026
SEC
Two C-suite insiders (CFO and Chief Medical Officer) sold ~$82K in open-market sales on 2026-05-18, while a director bou
CLUSTER — Impact 3/10
May 20, 2026
short_volume
Short Volume: HUMA — 62.0% short (1.3M / 2.2M)
Short: 1,347,384 | Exempt: 3,336 | TRF Vol: 2,172,438 | Short Ratio: 62.0% | Off-exchange volume (da
May 19, 2026
Insider
Sebelius Kathleen bought 56,818 shares
Director @ $0.8800 ($50.0K)
May 18, 2026
Insider
Parikh Shamik J sold 45,887 shares
Chief Medical Officer @ $0.8967 ($41.1K)
May 18, 2026
Insider
Sander Dale A. sold 45,887 shares
CFO and Chief Corp. Dev. Off @ $0.8967 ($41.1K)
May 13, 2026
SEC
Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both
PRESS-RELEASE — Impact 6/10
May 8, 2026
SEC
Humacyte announced it will release Q1 2026 financial results on May 13, 2026, with no preliminary financial data or guid
PRESS-RELEASE — Impact 2/10
Inst.
WELLS FARGO & COMPANY/MN — ADD
174,470 shares ($167.6K)
Price Targets
$5.00
+416.0% upside
Strong Buy
Current $0.9690
Low $1.00
Median $1.50
High $25.00
7 analysts
$1.00
$25.00
Analyst Ratings
3Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 13, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 24, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▼ -6.7% | $-0.14 — $-0.11 | 50% YoY | 4 |
| Next Q | $-0.09 ▲ +14.0% | $-0.10 — $-0.07 | 16% YoY | 4 |
| Current FY | $-0.39 ▲ +9.8% | $-0.43 — $-0.36 | -51% YoY | 4 |
| Next FY | $-0.16 ▲ +12.7% | $-0.31 — $0.11 | 59% YoY | 3 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two C-suite insiders (CFO and Chief Medical Officer) sold ~$82K in open-market sales on 2026-05-18, while a director bou
May 20, 2026
MIXED
PRESS-RELEASE
6/10
Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both
May 13, 2026
BULLISH
Press
7/10
Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Symvess) has been accep
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.1M | — |
| MORGAN STANLEY | $2.4M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.4M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.2M | NEW |
| BANK OF AMERICA CORP | $434.1K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | Sebelius Kathleen | BUY | $50.0K |
| May 18, 2026 | Parikh Shamik | SELL | $41.1K |
| May 18, 2026 | Sander Dale | SELL | $41.1K |
| May 18, 2026 | Constantino Michael | BUY | $9.8K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $13.7M total value (14,286,838 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,416,971 | $8.1M | 58.9% | — |
| 2 | MORGAN STANLEY | 2,505,428 | $2.4M | 17.5% | ADD +52.3% |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,491,467 | $1.4M | 10.4% | DOUBLED +162.2% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,239,477 | $1.2M | 8.7% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 452,208 | $434.1K | 3.2% | TRIM -44.1% |
| 6 | WELLS FARGO & COMPANY/MN | 174,470 | $167.6K | 1.2% | ADD +78.0% |
| 7 | FMR LLC | 6,817 | $6.5K | 0.0% | DOUBLED +140.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | ADD | 98,021 | 174,470 | +78.0% | $167.6K | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,376,595 | 2,096,753 | +52.3% | $3.6M | 2025-Q3 |
| UBS Group AG | ADD | 1,425,855 | 2,445,471 | +71.5% | $5.1M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 586,441 | 1,537,381 | +162.2% | $3.2M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 580,370 | 1,376,595 | +137.2% | $2.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 900,805 | 503,319 | -44.1% | $1.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 48,603 | 81,808 | +68.3% | $171.0K | 2025-Q2 |
| FMR LLC | DOUBLED | 3,241 | 7,808 | +140.9% | $16.3K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 591,562 | 3,680,401 | +522.1% | $6.3M | 2025-Q1 |
| UBS Group AG | ADD | 1,121,552 | 1,425,855 | +27.1% | $2.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 919,097 | 586,441 | -36.2% | $999.9K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 25,578 | 3,241 | -87.3% | $5.5K | 2025-Q1 |
| UBS Group AG | DOUBLED | 184,013 | 1,121,552 | +509.5% | $5.7M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 35,805 | 50,454 | +40.9% | $254.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 721,318 | — | $3.9M | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 203,131 | 559,313 | +175.3% | $3.0M | 2024-Q3 |
4 unique insiders with 4 transactions. Net insider value: -$22.5K ($59.8K bought, $82.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Sebelius Kathleen | Director | BUY | 56,818 | $0.8800 | $50.0K |
| May 18, 2026 | Parikh Shamik J | Chief Medical Officer | SELL | 45,887 | $0.8967 | $41.1K |
| May 18, 2026 | Sander Dale A. | CFO and Chief Corp. Dev. Off | SELL | 45,887 | $0.8967 | $41.1K |
| May 18, 2026 | Constantino Michael T. | Director | BUY | 11,000 | $0.8945 | $9.8K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.7/10.
NEUTRAL
CLUSTER
3/10
Two C-suite insiders (CFO and Chief Medical Officer) sold ~$82K in open-market sales on 2026-05-18,
May 20, 2026
MIXED
PRESS-RELEASE
6/10
Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consens
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Humacyte announced it will release Q1 2026 financial results on May 13, 2026, with no preliminary fi
May 8, 2026
BULLISH
7/10
Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Sym
Apr 21, 2026
NEUTRAL
3/10
Humacyte announced it will release its Q4 and full-year 2025 financial results on March 27, 2026, fo
Mar 23, 2026
MIXED
5/10
Humacyte announced a $1.475 million binding purchase commitment for its Symvess product to support a
Mar 19, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+416.0% upside
Strong Buy (1.57)
$1.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9690 |
| Target Low | $1.00 |
| Target Mean | $5.00 |
| Target Median | $1.50 |
| Target High | $25.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.14 | $-0.11 | 50.0% | -6.7% | 1↑ 1↓ | $0.0B | 241.1% | 4 |
| Next Q 2026-09-30 |
$-0.09 | $-0.10 | $-0.07 | 15.9% | +14.0% | 2↑ 1↓ | $0.0B | 174.4% | 4 |
| Current FY 2026-12-31 |
$-0.39 | $-0.43 | $-0.36 | -51.0% | +9.8% | 2↑ 1↓ | $0.0B | 198.4% | 4 |
| Next FY 2027-12-31 |
$-0.16 | $-0.31 | $0.11 | 59.2% | +12.7% | 1↑ 1↓ | $0.1B | 764.4% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.113 | -0.007 |
| 30d ago | $-0.113 | -0.007 |
| 60d ago | $-0.110 | -0.010 |
| 90d ago | $-0.110 | -0.010 |
6 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 24, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 31, 2026 | Benchmark | DOWNGRADE | Buy | Speculative Buy |
| Mar 30, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Mar 30, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | Benchmark | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
7 mentions
0 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 1, 2026 | 4 | 50° Neutral | 0 | 0 | 4 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$HUMA - The Future is now
▲ 1
💬 0
⚡ 0.5
May 20, 2026
short_volume
Short Volume: HUMA — 62.0% short (1.3M / 2.2M)
Short: 1,347,384 | Exempt: 3,336 | TRF Vol: 2,172,438 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: HUMA — 75.3% short (1.8M / 2.3M)
Short: 1,755,117 | Exempt: 100 | TRF Vol: 2,330,747 | Short Ratio: 75.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: HUMA — 61.6% short (2.8M / 4.5M)
Short: 2,775,372 | Exempt: 353,996 | TRF Vol: 4,504,437 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: HUMA — 70.0% short (3.4M / 4.9M)
Short: 3,427,762 | Exempt: 86,738 | TRF Vol: 4,899,758 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - </em></p>
May 13, 2026
earnings_calendar
HUMA Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
other
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
<p align="center"><em>- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge b
May 12, 2026
short_volume
Short Volume: HUMA — 56.5% short (1.6M / 2.8M)
Short: 1,597,082 | Exempt: 3,163 | TRF Vol: 2,826,225 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
HUMA Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
earnings
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
<p>DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing univer
May 8, 2026
earnings_calendar
HUMA Q1 2026 Earnings Scheduled — 2026-05-08
May 5, 2026
short_volume
Short Volume: HUMA — 55.6% short (1.4M / 2.5M)
Short: 1,402,025 | Exempt: 85 | TRF Vol: 2,522,642 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: HUMA — 57.8% short (1.7M / 2.9M)
Short: 1,677,885 | Exempt: 8,650 | TRF Vol: 2,903,225 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_volume
Short Volume: HUMA — 55.4% short (0.9M / 1.7M)
Short: 927,683 | Exempt: 510 | TRF Vol: 1,673,706 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: HUMA — 56.8% short (1.1M / 1.9M)
Short: 1,092,996 | Exempt: 21,578 | TRF Vol: 1,923,053 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)